1 unknown, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Heart Failure NYHA Class II: new trials by email Literature Review of Heart Failure NYHA Class II trials Research Report on Heart Failure NYHA Class II
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biomarker Study: Heart Failure Patients at Risk Angiotensin 1-7, Saline solution - Heart Failure NYHA Class II, Heart Failure NYHA Class III | Phase 1 / Phase 2 | Unknown | University of Arizona | 40 | 2022-04-01 | 2022-04-20 |
| Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2 Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid - Heart Failure NYHA Class I, Heart Failure NYHA Class II | Phase 2 | Withdrawn | Vanderbilt University Medical Center | 2017-09-01 | 2018-01-11 |
Heart Failure (1)
Cardiovascular Diseases (1) · Heart Diseases (1)
BID protein, human (1) · Enalapril (1) · Saline Solution (1) · Valsartan (1) · angiotensin I (1-7) (1) · icatibant (1) · sacubitril and valsartan sodium hydrate drug combination (1)
University of Arizona (1) · Vanderbilt University Medical Center (1)
United States (2)
Lee Ryan, Ph.D. (1)